Posted by Michael Wonder on 11 Dec 2019
Venturing a perspective on the drug pricing debate
10 December 2019 - The perennial drug pricing debate has reached a fever pitch, as loud as it’s ever been over the past few decades.
Politicians on both sides are bashing the drug industry with the typical talking points about exorbitant prices, countered of course by the expected talking points about innovation and impact from PhRMA and BIO. Even VC’s and biotech CEOs are actively engaged in letter-writing campaigns to support the industry.
This week Congress is considering a piece of proposed legislation, known as “The Lower Drug Costs Now Act”, which is similar in form to many of the proposals from multiple presidential candidates (like Elizabeth Warren). Let there be no mistake: these proposals would fundamentally damage the landscape for biomedical innovation in the US.
